Open Access

REVIEW

MicroRNA in HCC: Biomarkers and Therapeutic Targets

Zheng Wang¹, Yongxia He¹, Yuwei Song¹, Yue Wang², Feng Chen^3,*

1 Food and Drug Department, Luoyang Polytechnic, Luoyang, 471000, China
2 Department of Pharmacology and Toxicology, Wright State University, Dayton, 45435, USA
3 Department of Internal Medicine, The 11th People’s Hospital of Luoyang City, Luoyang, 471000, China

* Corresponding Author: Feng Chen. Email:

Oncologie 2021, 23(2), 177-184. https://doi.org/10.32604/Oncologie.2021.014773

Received 28 October 2020; Accepted 02 April 2021; Issue published 22 June 2021

Abstract

Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality. At present, diagnostic methods such as imaging observation, serum testing and tissue biopsy, as well as treatment methods such as surgical resection, radiotherapy, and chemotherapy have certain limitations in clinical interventions for HCC due to the complex pathogenesis and drug resistance of liver cancer, which seriously affect the survival and prognosis of patients. As a large-scale cytokine, microRNA (miRNA) plays an important role in regulating various life activities of cells. Extensive evidence proved that certain miRNAs are specifically expressed in the tissues and blood of HCC patients, and some of them have been confirmed as important factors that can participate in the regulation of key signaling pathways in cancer cells. For this reason, these miRNAs have great potential in clinical diagnosis and treatment of HCC, and can improve the limitations of conventional diagnosis and treatment. Our paper reviews the research on miRNA biomarkers and targets in HCC in recent years, and aims to provide new ideas for the diagnosis and treatment of HCC.

---

Keywords

---

Citations